Inflammatory bowel disease-associated thromboembolism

A systematic review of outcomes with anticoagulation versus catheter-directed thrombolysis

James H. Tabibian, Michael B. Streiff

Research output: Contribution to journalReview article

16 Citations (Scopus)

Abstract

Background: Thromboembolism (TE) is a common extraintestinal complication of inflammatory bowel disease (IBD). Catheter-directed thrombolysis (CDT) is being increasingly used to treat TE but often evokes fears of hemorrhagic complications (HCs) in patients with IBD. We reviewed clinical outcomes with anticoagulation (AC) and CDT in IBD patients with TE. Methods: Published cases of IBD patients with TE were identified by a PubMed search. Cases were divided into two groups based on treatment modality: AC alone or CDT. Pretreatment variables and treatment-related outcomes were compared between treatment groups. Results: Fifty-two cases of IBD-associated TE were identified. Thirty-five cases were treated with AC alone and 17 with CDT. There were no significant differences in pretreatment variables. Patients treated with CDT tended to be more likely to achieve complete or partial symptomatic (P = 0.02) and radiologic resolution (P = 0.06). Gastrointestinal (GI) and non-GI HCs tended to occur more frequently with CDT, although these differences were not statistically significant (P = 0.44 and 0.15, respectively). Conclusions: CDT and AC both appear to be well tolerated by IBD patients with TE. CDT may be used preferentially in patients with life-threatening TE, while AC may be preferable in patients with less clinically significant TE or patients at higher risk for bleeding. Further prospective studies are warranted to confirm these results and more definitively identify the best therapeutic approach for patients with IBD-associated TE.

Original languageEnglish (US)
Pages (from-to)161-171
Number of pages11
JournalInflammatory Bowel Diseases
Volume18
Issue number1
DOIs
StatePublished - Jan 2012
Externally publishedYes

Fingerprint

Thromboembolism
Inflammatory Bowel Diseases
Catheters
PubMed
Fear
Therapeutics
Prospective Studies
Hemorrhage

Keywords

  • colitis
  • gastrointestinal hemorrhage
  • inflammatory bowel disease
  • thromboembolism
  • thrombolytic therapy

ASJC Scopus subject areas

  • Gastroenterology
  • Immunology and Allergy

Cite this

Inflammatory bowel disease-associated thromboembolism : A systematic review of outcomes with anticoagulation versus catheter-directed thrombolysis. / Tabibian, James H.; Streiff, Michael B.

In: Inflammatory Bowel Diseases, Vol. 18, No. 1, 01.2012, p. 161-171.

Research output: Contribution to journalReview article

@article{2fbc31d50b394863ad54331457596073,
title = "Inflammatory bowel disease-associated thromboembolism: A systematic review of outcomes with anticoagulation versus catheter-directed thrombolysis",
abstract = "Background: Thromboembolism (TE) is a common extraintestinal complication of inflammatory bowel disease (IBD). Catheter-directed thrombolysis (CDT) is being increasingly used to treat TE but often evokes fears of hemorrhagic complications (HCs) in patients with IBD. We reviewed clinical outcomes with anticoagulation (AC) and CDT in IBD patients with TE. Methods: Published cases of IBD patients with TE were identified by a PubMed search. Cases were divided into two groups based on treatment modality: AC alone or CDT. Pretreatment variables and treatment-related outcomes were compared between treatment groups. Results: Fifty-two cases of IBD-associated TE were identified. Thirty-five cases were treated with AC alone and 17 with CDT. There were no significant differences in pretreatment variables. Patients treated with CDT tended to be more likely to achieve complete or partial symptomatic (P = 0.02) and radiologic resolution (P = 0.06). Gastrointestinal (GI) and non-GI HCs tended to occur more frequently with CDT, although these differences were not statistically significant (P = 0.44 and 0.15, respectively). Conclusions: CDT and AC both appear to be well tolerated by IBD patients with TE. CDT may be used preferentially in patients with life-threatening TE, while AC may be preferable in patients with less clinically significant TE or patients at higher risk for bleeding. Further prospective studies are warranted to confirm these results and more definitively identify the best therapeutic approach for patients with IBD-associated TE.",
keywords = "colitis, gastrointestinal hemorrhage, inflammatory bowel disease, thromboembolism, thrombolytic therapy",
author = "Tabibian, {James H.} and Streiff, {Michael B.}",
year = "2012",
month = "1",
doi = "10.1002/ibd.21307",
language = "English (US)",
volume = "18",
pages = "161--171",
journal = "Inflammatory Bowel Diseases",
issn = "1078-0998",
publisher = "John Wiley and Sons Inc.",
number = "1",

}

TY - JOUR

T1 - Inflammatory bowel disease-associated thromboembolism

T2 - A systematic review of outcomes with anticoagulation versus catheter-directed thrombolysis

AU - Tabibian, James H.

AU - Streiff, Michael B.

PY - 2012/1

Y1 - 2012/1

N2 - Background: Thromboembolism (TE) is a common extraintestinal complication of inflammatory bowel disease (IBD). Catheter-directed thrombolysis (CDT) is being increasingly used to treat TE but often evokes fears of hemorrhagic complications (HCs) in patients with IBD. We reviewed clinical outcomes with anticoagulation (AC) and CDT in IBD patients with TE. Methods: Published cases of IBD patients with TE were identified by a PubMed search. Cases were divided into two groups based on treatment modality: AC alone or CDT. Pretreatment variables and treatment-related outcomes were compared between treatment groups. Results: Fifty-two cases of IBD-associated TE were identified. Thirty-five cases were treated with AC alone and 17 with CDT. There were no significant differences in pretreatment variables. Patients treated with CDT tended to be more likely to achieve complete or partial symptomatic (P = 0.02) and radiologic resolution (P = 0.06). Gastrointestinal (GI) and non-GI HCs tended to occur more frequently with CDT, although these differences were not statistically significant (P = 0.44 and 0.15, respectively). Conclusions: CDT and AC both appear to be well tolerated by IBD patients with TE. CDT may be used preferentially in patients with life-threatening TE, while AC may be preferable in patients with less clinically significant TE or patients at higher risk for bleeding. Further prospective studies are warranted to confirm these results and more definitively identify the best therapeutic approach for patients with IBD-associated TE.

AB - Background: Thromboembolism (TE) is a common extraintestinal complication of inflammatory bowel disease (IBD). Catheter-directed thrombolysis (CDT) is being increasingly used to treat TE but often evokes fears of hemorrhagic complications (HCs) in patients with IBD. We reviewed clinical outcomes with anticoagulation (AC) and CDT in IBD patients with TE. Methods: Published cases of IBD patients with TE were identified by a PubMed search. Cases were divided into two groups based on treatment modality: AC alone or CDT. Pretreatment variables and treatment-related outcomes were compared between treatment groups. Results: Fifty-two cases of IBD-associated TE were identified. Thirty-five cases were treated with AC alone and 17 with CDT. There were no significant differences in pretreatment variables. Patients treated with CDT tended to be more likely to achieve complete or partial symptomatic (P = 0.02) and radiologic resolution (P = 0.06). Gastrointestinal (GI) and non-GI HCs tended to occur more frequently with CDT, although these differences were not statistically significant (P = 0.44 and 0.15, respectively). Conclusions: CDT and AC both appear to be well tolerated by IBD patients with TE. CDT may be used preferentially in patients with life-threatening TE, while AC may be preferable in patients with less clinically significant TE or patients at higher risk for bleeding. Further prospective studies are warranted to confirm these results and more definitively identify the best therapeutic approach for patients with IBD-associated TE.

KW - colitis

KW - gastrointestinal hemorrhage

KW - inflammatory bowel disease

KW - thromboembolism

KW - thrombolytic therapy

UR - http://www.scopus.com/inward/record.url?scp=83555166106&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=83555166106&partnerID=8YFLogxK

U2 - 10.1002/ibd.21307

DO - 10.1002/ibd.21307

M3 - Review article

VL - 18

SP - 161

EP - 171

JO - Inflammatory Bowel Diseases

JF - Inflammatory Bowel Diseases

SN - 1078-0998

IS - 1

ER -